ALC
What one share of Alcon holds
Ophthalmic Goods
With $10.3 billion in net sales during the year ended December 31, 2025, we are the global leader in eye care. Our broad range of products represents one of the most complete portfolios in the ophthalmic industry and comprises high-quality and technologically advanced products across all major product categories in the surgical and vision care markets.
Alcon’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $20.96 |
|---|---|
| Profit | $1.98 |
| Capex (buildings and equipment) | $1.09 |
| Free cash flow | $3.48 |
| Dividends | $0.34 |
| Cash and investments | $3.13 |
| Debt | $9.72 |
| Book value | $45.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2008 | $20.87 | $6.79 | $1.00 | $5.74 | — | $15.71 |
| 2009 | $21.57 | $6.66 | $1.13 | $6.88 | — | $19.71 |
| 2010 | $23.61 | $7.27 | $1.02 | $6.79 | — | $23.98 |
| 2021 | $16.80 | $0.76 | $1.42 | $1.31 | — | $39.29 |
| 2022 | $17.63 | $0.68 | $1.29 | $1.18 | — | $40.15 |
| 2023 | $19.04 | $1.96 | $1.33 | $1.47 | — | $41.81 |
| 2024 | $19.92 | $2.05 | $0.95 | $3.22 | — | $43.58 |
| 2025 | $20.96 | $1.98 | $1.09 | $3.48 | — | $45.20 |